Download MendeleyAssociation of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors: A Phase 1b/2a Nonrandomized Clinical Trial.
Wagner, A.J., Severson, P.L., Shields, A.F., Patnaik, A., Chugh, R., Tinoco, G., Wu, G., Nespi, M., Lin, J., Zhang, Y., Ewing, T., Habets, G., Burton, E.A., Matusow, B., Tsai, J., Tsang, G., Shellooe, R., Carias, H., Chan, K., Rezaei, H., Sanftner, L., Marimuthu, A., Spevak, W., Ibrahim, P.N., Inokuchi, K., Alcantar, O., Michelson, G., Tsiatis, A.C., Zhang, C., Bollag, G., Trent, J.C., Tap, W.D.(2021) JAMA Oncol 7: 1343-1350
- PubMed: 34236401
- DOI: https://doi.org/10.1001/jamaoncol.2021.2086
- Primary Citation of Related Structures:
7KHG, 7KHJ, 7KHK - PubMed Abstract:
Many cancer subtypes, including KIT-mutant gastrointestinal stromal tumors (GISTs), are driven by activating mutations in tyrosine kinases and may initially respond to kinase inhibitors but frequently relapse owing to outgrowth of heterogeneous subclones with resistance mutations. KIT inhibitors commonly used to treat GIST (eg, imatinib and sunitinib) are inactive-state (type II) inhibitors.
Organizational Affiliation:
Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
